{"filing":{"accession_number":"0001140361-26-026232","cik":"0000874015","ticker":"IONS","company_name":"IONIS PHARMACEUTICALS INC","form":"8-K","filing_date":"2026-06-24","report_date":null,"primary_document":"ef20076807_8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/874015/000114036126026232/ef20076807_8k.htm"},"events":[{"id":13460,"run_id":11959,"accession_number":"0001140361-26-026232","anchor_item_number":"8.01","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Ionis announced FDA approval of TRYNGOLZA (olezarsen) for severe hypertriglyceridemia on June 24, 2026, based on positive Phase 3 CORE and CORE2 trial results. This represents the company's first independent commercial launch in a prevalent disease and a significant regulatory milestone for its novel RNA-targeted therapy platform.","company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","filing_date":"2026-06-24","form":"8-K","submitted_at":null,"items":[{"id":10601,"accession_number":"0001140361-26-026232","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Ionis announced FDA approval of TRYNGOLZA (olezarsen) for severe hypertriglyceridemia on June 24, 2026. This is a material regulatory milestone and product approval event that does not fit the specific taxonomy categories. While it is clearly operational/strategic in nature (a major product approval and commercial launch milestone), it is not a merger, acquisition, workforce reduction, or other specifically-named operational event. The approval represents a significant business development for Ionis' first independent commercial launch in a prevalent disease, making it material to investors assessing the company's pipeline and commercial prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-24T19:49:40.864316+00:00","company_name":"","ticker":null,"filing_date":""},{"id":10602,"accession_number":"0001140361-26-026232","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Ionis announced FDA approval of TRYNGOLZA (olezarsen) for severe hypertriglyceridemia on June 24, 2026, based on positive Phase 3 CORE and CORE2 trial results. This is a major regulatory milestone and product approval event that is clearly material to investors—it represents the company's first independent commercial launch in a prevalent disease and demonstrates successful development of a novel RNA-targeted therapy. While not fitting the specific categories of earnings release, M\u0026A, or other named event types, this regulatory approval and commercial launch milestone is a significant operational and strategic event for the company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-24T19:49:40.864316+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":10601,"accession_number":"0001140361-26-026232","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Ionis announced FDA approval of TRYNGOLZA (olezarsen) for severe hypertriglyceridemia on June 24, 2026. This is a material regulatory milestone and product approval event that does not fit the specific taxonomy categories. While it is clearly operational/strategic in nature (a major product approval and commercial launch milestone), it is not a merger, acquisition, workforce reduction, or other specifically-named operational event. The approval represents a significant business development for Ionis' first independent commercial launch in a prevalent disease, making it material to investors assessing the company's pipeline and commercial prospects.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-24T19:49:40.864316+00:00","company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","filing_date":"2026-06-24"},{"id":10602,"accession_number":"0001140361-26-026232","item_number":"8.01","item_title":"Other Events.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Ionis announced FDA approval of TRYNGOLZA (olezarsen) for severe hypertriglyceridemia on June 24, 2026, based on positive Phase 3 CORE and CORE2 trial results. This is a major regulatory milestone and product approval event that is clearly material to investors—it represents the company's first independent commercial launch in a prevalent disease and demonstrates successful development of a novel RNA-targeted therapy. While not fitting the specific categories of earnings release, M\u0026A, or other named event types, this regulatory approval and commercial launch milestone is a significant operational and strategic event for the company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-06-24T19:49:40.864316+00:00","company_name":"IONIS PHARMACEUTICALS INC","ticker":"IONS","filing_date":"2026-06-24"}]}